Evidence mapPaperPMID 35137148Full record

ArticleThe Journal of clinical endocrinology and metabolism2022

Approach to the Patient: "Utility of the Copeptin Assay".

Mirjam Christ-Crain, Julie Refardt, Bettina Winzeler

Open access · hybridAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Copeptin in the diagnosis and management of renal tubular disorders.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  5. Article
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Copeptin analysis in endocrine disorders.Frontiers in endocrinology · 2023
    Review
  16. Renal water transport in health and disease.Pflugers Archiv : European journal of physiology · 2022
    Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mirjam Christ-CrainDepartment of Endocrinology, Diabetes and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0002-6336-0965
Julie RefardtDepartment of Endocrinology, Diabetes and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0002-3040-4685
Bettina WinzelerDepartment of Endocrinology, Diabetes and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0001-8305-2700
University Hospital of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copeptin derives from the same precursor peptide preprovasopressin as arginine vasopressin (AVP). The secretion of both peptides is stimulated by similar physiological processes, such as osmotic stimulation, hypovolemia, or stress. AVP is difficult to measure due to complex preanalytical requirements and due to technical difficulties. In the last years, copeptin was found to be a stable, sensitive, and simple to measure surrogate marker of AVP release. Different immunoassays exist to measure copeptin. The 2 assays which have most often be used in clinical studies are the original sandwich immunoluminometric assay and its automated immunofluorescent successor. In addition, various enzyme-linked immunosorbent assay have been developed. With the availability of the copeptin assay, the differential diagnosis of diabetes insipidus was recently revisited. The goal for this article is therefore to first review the physiology of copeptin, and second to describe its use as marker for the differential diagnosis of vasopressin-dependent fluid disorders, mainly diabetes insipidus but also hyper- and hyponatremia. Furthermore, we highlight the role of copeptin as prognostic marker in other acute and chronic diseases.

Indexed as

Diabetes InsipidusHyponatremiaArginine VasopressinBiomarkersGlycopeptidesHumansArginine VasopressinBiomarkerscopeptinsGlycopeptidescopeptindiabetes insipidusdiagnosishypernatremiahyponatremiaprimary polydipsiaSIAD

Identifiers

PMID35137148
PMCPMC9113794
OpenAlexW4210939706

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.